Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (NCT03847428)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
🩺 Plain-English Summary (8th-Grade Level)
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
Who can join: Review the eligibility criteria below.
Location: Research Site — Birmingham, Alabama
Age range: 18 Years to 150 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (217 Sites)
Showing the first 25 of 217 sites.
- Research Site — Birmingham, Alabama
- Research Site — Mobile, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Costa Mesa, California
- Research Site — La Jolla, California
- Research Site — Long Beach, California
- Research Site — Orange, California
- Research Site — Sacramento, California
- Research Site — Washington D.C., District of Columbia
- Research Site — Miami, Florida
- Research Site — Tampa, Florida
- Research Site — Honolulu, Hawaii
- Research Site — Chicago, Illinois
- Research Site — Westwood, Kansas
- Research Site — Louisville, Kentucky
- Research Site — Shreveport, Louisiana
- Research Site — Detroit, Michigan
- Research Site — Grand Rapids, Michigan
- Research Site — Rochester, Minnesota
- Research Site — Omaha, Nebraska
- Research Site — New Brunswick, New Jersey
- Research Site — Albuquerque, New Mexico
- Research Site — New York, New York
- Research Site — Stony Brook, New York
- Research Site — Durham, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.